NLRP6 and metabolic dysfunction-associated steatotic liver disease: For example, in Lee's NAFLD mouse model, PPAR-δ agonists may inhibit the activation of NLRP6 inflammasome and reduce the level of IL-1β by regulating AMP-activated protein kinase phosphorylation and reducing reactive oxygen species (ROS) production, and the resulting anti-inflammatory effects may improve liver steatosis in mice [73].